Background: An association has been demonstrated between periodontal disease (PD) and rheumatoid arthritis. Less data is available for systemic lupus erythematosus (SLE) but on meta-analysis of eight studies including 1,383 participants, risk of PD in SLE cases compared to controls was significantly greater with a risk ratio of 1.76 (95% CI 1.29-2.41, p ¼ 0.0004). Our objective was to assess PD severity in participants with SLE in a London tertiary centre. Methods: SLE patients (diagnosis by rheumatologist þ Anti dsDNA/ Anti Sm positive) were compared to healthy controls and noninflammatory osteoarthritis (OA) control patients. Measures of periodontal disease were ascertained by a blinded examiner. Periodontitis was defined according to Eke & Page classification. Kruskal-Wallis test and Chi-square test were applied to test numerical and categorical data respectively. Spearman's correlation and linear regression were used to test for correlations. Results: 100% of participants in the SLE and controls groups had either mild, moderate or severe periodontitis. All measures of PD were similar in the three groups (Table 1) $table_{44297AB4-8E3C-4A47-B3F1-50358A8087B5}$$ On subgroup analysis of SLE patients, there was a significant correlation between ESR and bleeding on probing (r 2 ¼0.64, p ¼ 0.015). This was still significant after adjustments for BILAG and SLEDAI 2K. Conclusion: PD severity was similar in SLE patients and healthy controls, in contrast to the results of our meta-analysis. Possible explanations include the high rates of PD in all participants, mild disease severity in SLE patients and small sample size. Larger studies in this population are needed to elucidate the relationship further. OA patients had greater prevalence of severe periodontitis but this may be accounted for by age, a known risk factor for PD. ESR correlated with bleeding on probing independent of SLE severity. We suggest that SLE patients should be offered a dental assessment, especially if ESR is high. Disclosures: The authors have declared no conflicts of interest. Background: Fatigue is considered to be one of the most pervasive and disabling aspects of SLE. The pathogenesis of fatigue is poorly understood and therapeutic options are consequentially limited. Poorly functioning mitochondria -the primary sites of cellular energy generation -may be implicated in fatigue. Since SLE patients commonly describe their fatigue to be physical in nature and attribute this as local to their skeletal muscles, we hypothesised that skeletal muscle mitochondrial dysfunction existed among SLE patients which in turn related to physical fatigue. Methods: A case control 31 P MR Spectroscopy (MRS) study was conducted. Cases were SLE patients who fulfilled 1987 ACR criteria; reported chronic (>three months) clinically relevant fatigue (defined as a score of > 3 on the Chalder fatigue binary scale, CFS) and had inactive disease (defined as BILAG2004¼0, excluding the fatigueconstitutional domain). Controls were age/sex matched healthy members of the general population. Participants were scanned on a 3T whole body MR system where resting and dynamic (using within scanner exercise plantar flexion apparatus) MRS of the calf muscles was acquired. Physical fatigue was measured using the CFS Physical domain. In addition, all participants were characterised for co-variates of interest: current pain (VAS); depression (Hospital Anxiety & Depression Scale); sleep disturbance (Jenkins Sleep Scale); inflammation (ESR); and aerobic fitness (Siconolfi Step Test). Measures of ATP metabolism (phosphocreatine (PCr), pH, PCr recovery half time) were computed from the resting and dynamic MRS. These are considered valid markers of mitochondrial dysfunction. Simple descriptive statistics were applied to evaluate differences between cases and controls. Path analyses were undertaken to investigate if physical fatigue (or other co-variates of interest) mediated the relationship between mitochondrial dysfunction and group membership (i.e. case or control). Results: Among the 32 subjects (mean age¼ 43.5 years, 90.6% female), cases (n ¼ 16) reported higher levels of physical fatigue, pain, depression and sleep disturbance compared to the control group (p < 0.0001). PCr recovery half time, but no other measures of ATP metabolism, was significantly longer (p ¼ 0.046) among cases (32.99þ/-9.04s)) compared to controls (27.15þ/-6.62s). The relationship between caseness and PCr was not mediated by physical fatigue (b ¼ 0.074, 95% CI -0.54-0.72, p ¼ 0.81) or any of the other co-variates of interest except for pain (b ¼ 0.26, 95% CI 0.033-0.57, p ¼ 0.049). Conclusion: In this first study of MRS in SLE, we report preliminary data which indicates a degree of skeletal muscle mitochondrial dysfunction in SLE compared to healthy controls. This difference was explained by current levels of reported pain but not physical fatigue. Alternative mechanistic fatigue pathways should be explored, although in the future MRS may provide a useful biomarker to aid the study SLE related pain -another patient priority. Disclosures: NL.E. has a corporate appoimtnet with GSK and has shares in GSK. N.B., G.C., N.S., K.K., G.H., A.S., P.D., S.G., G.W. and J.H. have declared no conflicts of interest. 
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